Document Type : Original Article
Authors
- . Samaneh Assarzadeh 1
- . Sahar Vahdat 2
- . Shiva Seirafian 2
- . Morteza Pourfarzam 3
- . Shirinsadat Badri 4
1 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran
2 Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Clinical Biochemistry, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Objective: Trace elements deficiency is common among end‑stage renal
disease (ESRD) patients due to excessive loss during dialysis and the lower intake
secondary to loss of appetite. Selenium (Se) is a trace element that plays an important
role in the radical scavenging system and helps the body defend against oxidative
stress. This study aims to evaluate the effects of Se supplementation on lipid
profile, anemia, and inflammation indices in ESRD patients. Methods: Fifty-nine
hemodialysis patients enrolled and were randomly divided into two groups. Two
hundred microgram Se capsules once daily for the case group and matching placebo
for the control group were administered for three months. Demographic data
were collected at the study beginning. Uric acid (UA), anemia and inflammation
indices, and lipid profiles were recorded at the beginning and the end of the study.
Findings: UA and UA‑to‑HDL (high‑density lipoprotein) ratio decreased significantly
in the case group (P < 0.001). The changes in lipid profile were not significant among
both groups. Hemoglobin slightly increased in the case group, however, it decreased
significantly in the control group (P = 0.031). High-sensitivity C-reactive protein (hsCRP) decreased in the case group and increased in the control group, however, none
of these changes were significant. Conclusion: According to the results of this study,
selenium supplementation in ESRD patients could reduce some risk factors related to
their mortality, such as the ratio of uric acid to HDL. However, the changes related to
lipid profile, hemoglobin level and hs-CRP biomarker were not significant.
Keywords
Global trends in diabetes complications: A review of current
evidence. Diabetologia 2019;62:3-16.
2. Fujii H, Kono K, Nishi S. Characteristics of coronary artery
disease in chronic kidney disease. Clinical and experimental
nephrology 2019;23:725-32.
3. Ishigami J, Matsushita K. Clinical epidemiology of infectious
disease among patients with chronic kidney disease. Clin Exp
Nephrol 2019;23:437-47.
4. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN,
Kasiske BL, et al. Controlling the epidemic of cardiovascular
disease in chronic renal disease: What do we know? What do
we need to learn? Where do we go from here? National kidney
foundation task force on cardiovascular disease. Am J Kidney
Dis 1998;32:853-906.
5. Bossola M, Di Stasio E, Viola A, Leo A, Carlomagno G,
Monteburini T, et al. Dietary intake of trace elements, minerals,
and vitamins of patients on chronic hemodialysis. Int Urol
Nephrol 2014;46:809-15.
6. Brown KM, Arthur JR. Selenium, selenoproteins and human
health: A review. Public Health Nutr 2001;4:593-9.
7. Reich HJ, Hondal RJ. Why nature chose selenium. ACS Chem
Biol 2016;11:821-41.
8. Omrani H, Golmohamadi S, Pasdar Y, Jasemi K, Almasi
A. Effect of selenium supplementation on lipid profile in
hemodialysis patients. J Renal Inj Prev. 2016;5:179-82.
9. Khan MS, Dilawar S, Ali I, Rauf N. The possible role of
selenium concentration in hepatitis B and C patients. Saudi J
Gastroenterol 2012;18:106-10.
10. Tóth RJ, Csapó J. The role of selenium in nutrition – A review.
Acta Univ Sapientiae Aliment 2018;11:128-44.
11. Salehi M, Sohrabi Z, Ekramzadeh M, Fallahzadeh MK,
Ayatollahi M, Geramizadeh B, et al. Selenium supplementation
improves the nutritional status of hemodialysis patients:
A randomized, double-blind, placebo-controlled trial. Nephrol
Dial Transplant 2013;28:716-23.
12. Zachara BA, Gromadzinska J, Palus J, Zbrog Z, Swiech R,
Twardowska E, et al. The effect of selenium supplementation
in the prevention of DNA damage in white blood cells of
hemodialyzed patients: A pilot study. Biol Trace Elem Res
2011;142:274-83.
13. Atapour A, Vahdat S, Hosseini M, Mohamadian H. Effect of
selenium on triglyceride and total cholesterol, weight gain, and
physical activity on hemodialysis patients: A randomized doubleblinded controlled trial. Int J Prev Med 2022;13:63.
14. Park JH, Jo YI, Lee JH. Renal effects of uric acid: Hyperuricemia
and hypouricemia. Korean J Intern Med 2020;35:1291-304.
15. Rysz J, Gluba‑Brzózka A, Rysz‑Górzyńska M, Franczyk B.
The role and function of HDL in patients with chronic kidney
disease and the risk of cardiovascular disease. Int J Mol Sci
2020;21:E601.
16. Liu R, Peng Y, Wu H, Diao X, Ye H, Huang X, et al. Uric
acid to high-density lipoprotein cholesterol ratio predicts
cardiovascular mortality in patients on peritoneal dialysis. Nutr
Metab Cardiovasc Dis 2021;31:561-9.
17. Behera AK, Rathor PK, Nahak SR, Marndi C. The Correlation
Between High-Density Lipoprotein Cholesterol and Glomerular
Filtration Rate Estimation in a Community-Based Population.
European Journal of Molecular & Clinical Medicine
2022;9:3233-42.
18. Moore C Jr., Ormseth M, Fuchs H. Causes and significance of
markedly elevated serum ferritin levels in an academic medical
center. J Clin Rheumatol 2013;19:324-8.
19. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc
Nephrol 2012;23:1631-4.
20. Stenvinkel P, Lindholm B. C-reactive protein in end-stage
renal disease: Are there reasons to measure it? Blood Purif
2005;23:72-8.
21. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The
kynurenines are associated with oxidative stress, inflammation
and the prevalence of cardiovascular disease in patients with
end-stage renal disease. Atherosclerosis 2009;204:309-14.
22. Li W, Xiong L, Fan L, Wang Y, Peng X, Rong R, et al.
Association of baseline, longitudinal serum high-sensitive
C-reactive protein and its change with mortality in peritoneal
dialysis patients. BMC Nephrol 2017;18:211.
)